Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Teclistamab demonstrated efficacy and safety profiles in the China cohort consistent with the pivotal cohort, supporting teclistamab as a promising treatment option for triple-class exposed relapsed/refractory multiple myeloma in China.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2024-12-11
DOI
https://doi.org/10.1002/cncr.35665
Citations
6
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
2.73

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Yang Song, Zhongjun Xia, Xinchao Luo, Latisha Watkins et al.
6 citations
Cancer
Multiple Myeloma Research and Treatments
2.73
article

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Yang Song, Zhongjun Xia, Xinchao Luo, Latisha Watkins, Weijun Fu, Juanjuan Song, Aijun Liao, Raluca Verona, Juan Du, Natalia A. Quijano Cardé, Clarissa Uhlar, Ting Niu, Zhuolu Niu, Katherine Chastain, Lin Huang, Zhen Cai, Jingyun Li, Yafei Wang, Yue Guo, Hongmei Xu, Yujun Dong, Aili He, Longen Zhou
article en
6 citations

Abstract

Teclistamab demonstrated efficacy and safety profiles in the China cohort consistent with the pivotal cohort, supporting teclistamab as a promising treatment option for triple-class exposed relapsed/refractory multiple myeloma in China.

CancerVol. 131(1)
Sun Yat-sen University (CN), Peking University (CN), Sichuan University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), West China Hospital of Sichuan University (CN), Shanghai Changzheng Hospital (CN), Peking University First Hospital (CN), Second Affiliated Hospital of Xi'an Jiaotong University (CN), Sun Yat-sen University Cancer Center (CN), Janssen (United States) (US), First Affiliated Hospital Zhejiang University (CN), China Medical University (CN)
Janssen Research and Development
Openalex Percentile: Top 9%
Multiple Myeloma Research and Treatments
2.73
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.